Table 1. Changes in height in subgroups of patients receiving growth hormone treatment. Values are means (SD) unless otherwise specified

Treatment completed as scheduled
Treatment stopped early

Baseline:

  No (% boys) of patients 1524 (56)^** 1328 (74)

  Age (years) 12.9 (2.1)^** 12.3 (2.3)

  No (% boys) prepubertal 881 (55)^** 974 (72)

  No pubertal boys 371 287

  No pubertal girls 272 67

  Bone age (years) 10.6 (2.2)^** 9.8 (2.4)

  Height (SD score) $-$ 2.7 (0.8) $-$ 2.7 (0.8)

  Weight (SD score) $-$ 1.4 (0.9)^* $-$ 1.6 (0.8)

  Growth velocity (cm/year) 4.8 (1.8)^** 4.4 (1.5)

  Peak GH concentration (µg/l) 8.5 (3.6)^* 8.8 (3.5)

  Target height (SD score) $-$ 1.1 (1) $-$ 1.2 (1)

End of treatment:

  No 1524 1328

  Age (years) 16.6 (1.5) 15 (2.1)

  Duration of treatment (years) 3.6 (1.4) 2.7 (1.4)

  Height (SD score) $-$ 1.7 (0.8) $-$ 2.1 (0.9)

  Height (cm) (boys/girls) 163 (6)/151 (5) 152 (11)/141 (10)

  Change in height (SD score) 1.0 (0.7) 0.6 (0.6)

Adult height:

  No (% of patients at baseline) 1232 (81) 933 (70)

  Age (years) 20.8 (2.9) 20.9 (2.6)

  Total duration of follow up (years) 7.9 (2.2) 8.5 (1.7)

  Height (SD score) $-$ 1.6 (0.9) $-$ 1.5 (1)

  Height (cm, boys/girls) 167 (6)/154 (5) 167 (6)/154 (6)

  Change in height from end of treatment (SD score) 0.1 (0.5) 0.4 (0.9)

  Change in height from baseline (SD score) 1.1 (0.9) 1.1 (1)

SD=standard deviation.

Comparisons at baseline with patients who stopped treatment early (Student's t test and Kruskall-Wallis test for peak GH, P<0.01 considered to be significant, given the number of comparisons performed): ^*P<0.001; ^**P<0.0001.

Median (interquartile range).